1. Home
  2. ALT vs TWN Comparison

ALT vs TWN Comparison

Compare ALT & TWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • TWN
  • Stock Information
  • Founded
  • ALT 1997
  • TWN 1986
  • Country
  • ALT United States
  • TWN Hong Kong
  • Employees
  • ALT N/A
  • TWN N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • TWN Trusts Except Educational Religious and Charitable
  • Sector
  • ALT Health Care
  • TWN Finance
  • Exchange
  • ALT Nasdaq
  • TWN Nasdaq
  • Market Cap
  • ALT 292.0M
  • TWN 305.8M
  • IPO Year
  • ALT N/A
  • TWN N/A
  • Fundamental
  • Price
  • ALT $3.67
  • TWN $50.22
  • Analyst Decision
  • ALT Strong Buy
  • TWN
  • Analyst Count
  • ALT 6
  • TWN 0
  • Target Price
  • ALT $17.40
  • TWN N/A
  • AVG Volume (30 Days)
  • ALT 2.8M
  • TWN 20.1K
  • Earning Date
  • ALT 08-12-2025
  • TWN 01-01-0001
  • Dividend Yield
  • ALT N/A
  • TWN 1.10%
  • EPS Growth
  • ALT N/A
  • TWN N/A
  • EPS
  • ALT N/A
  • TWN N/A
  • Revenue
  • ALT $20,000.00
  • TWN N/A
  • Revenue This Year
  • ALT N/A
  • TWN N/A
  • Revenue Next Year
  • ALT $761,880.20
  • TWN N/A
  • P/E Ratio
  • ALT N/A
  • TWN N/A
  • Revenue Growth
  • ALT N/A
  • TWN N/A
  • 52 Week Low
  • ALT $2.90
  • TWN $25.22
  • 52 Week High
  • ALT $11.16
  • TWN $41.51
  • Technical
  • Relative Strength Index (RSI)
  • ALT 46.45
  • TWN 75.57
  • Support Level
  • ALT $3.35
  • TWN $47.76
  • Resistance Level
  • ALT $3.66
  • TWN $49.10
  • Average True Range (ATR)
  • ALT 0.18
  • TWN 0.56
  • MACD
  • ALT 0.05
  • TWN 0.09
  • Stochastic Oscillator
  • ALT 58.57
  • TWN 100.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About TWN Taiwan Fund Inc. (The)

Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.

Share on Social Networks: